Informing & Supporting Thyroid Patients Since 1985
Informing & Supporting Thyroid Patients Since 1985
Thyroid Research 
Thyroid Research Archive Hypothyroidism
(July 2002)
The background of the study. Thalidomide is an old drug, proven to cause birth defects, that was recently found to have beneficial effects in patients with multiple myeloma (a tumor of bone marrow) and other tumors. This article describes a patient with multiple myeloma who had hypothyroidism while receiving thalidomide and the results of measurements of serum thyrotropin (TSH) in other patients with multiple myeloma who were treated with thalidomide.
Case report. The patient was a 44-year-old man with multiple myeloma who had symptoms of hypothyroidism (cold intolerance, fatigue, depression) after four weeks of treatment with thalidomide therapy (400 mg daily). His symptoms persisted after the dose of thalidomide was reduced to 200 mg daily. At three months, his serum TSH concentration was very high (115 mU/L) and his serum thyroxine concentration was low. He was treated with T4.
How the study was done and the results of the study. Serum TSH was measured in two groups of patients. One group consisted of 174 patients with multiple myeloma who were randomly assigned to receive chemotherapy and thalidomide, 400 mg daily, or chemotherapy alone. Three to four months later, 18 of the 92 patients (20 percent) in the chemotherapy and thalidomide group had serum TSH concentrations >5 mU/L, as compared with 7 of the 82 patients (9 percent) in the chemotherapy-alone group. Six patients (7 percent) in the chemotherapy and thalidomide group, but none in the chemotherapy group, had a serum TSH concentration >10 mU/L (range, 12 to 114).
The second group consisted of 81 patients with multiple myeloma. During treatment with 200 to 800 mg of thalidomide daily for two to six months, their median serum TSH concentration increased by 48 percent. Eighteen patients (22 percent) had serum TSH concentrations >5 mU/L, and 11 (14 percent) had concentrations ≥10 mU/L.
Symptoms were not recorded and serum T4 was not measured in these patients.
The conclusions of the study. Thalidomide has an antithyroid action in patients with multiple myeloma.
The original article. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002;112:412-3.
Your Help Can Make a Difference!
Join us in helping to educate and support thyroid patients, their families, physicians, and other health care professionals and to increase public awareness of thyroid disorders.
Thanks to all of our donors for helping to make a difference!
